How Much Hydralazine Can You Take in a Day?

The standard maximum oral dose of hydralazine is 300 mg per day, split across multiple doses. Most prescribers, however, keep patients at or below 200 mg per day because the risk of a serious autoimmune side effect climbs steeply above that threshold. How much you actually end up taking depends on several factors that are surprisingly individual, including your genetic makeup, kidney function, and whether you are taking hydralazine for high blood pressure or heart failure.

Standard Oral Dosing

Hydralazine is typically started at a low dose and increased gradually. A common starting regimen is 10 mg taken four times a day for the first two to four days, then 25 mg four times a day for the rest of the first week or so. From there, the dose is adjusted based on blood pressure response. Most people end up somewhere between 100 and 200 mg per day, divided into two to four doses. The labeled ceiling is 300 mg per day, but reaching that level is unusual because side effects become more likely and because other blood pressure medications are usually added before pushing hydralazine that high.

Hydralazine’s effect on blood pressure wears off relatively quickly, which is why it is usually dosed multiple times a day rather than once. The drug works by relaxing the smooth muscle in blood vessel walls. Research in animal models has shown that its main action involves blocking the release of calcium inside vascular smooth muscle cells, which prevents those cells from contracting and narrowing the vessel.¹ In smaller resistance arteries, a separate mechanism kicks in at clinically relevant concentrations: hydralazine triggers the release of a substance called prostacyclin from the vessel lining, which also promotes relaxation.² In larger arteries, the relaxation appears to happen independently of the vessel lining altogether.³

Why Your Genetics Affect the Dose You Need

One of the most striking things about hydralazine is how much your genetic acetylator status influences its effect. Your liver breaks down hydralazine through an enzyme called NAT2, and people fall into roughly two camps: “slow acetylators,” whose enzyme works at a leisurely pace, and “rapid acetylators,” whose enzyme chews through the drug quickly. This is not a small difference. Studies using precise assay methods have found that slow acetylators absorb roughly 30 to 35 percent of an oral dose into their bloodstream, while rapid acetylators absorb only about 10 to 16 percent of the same dose.⁴ That means a rapid acetylator may need two or three times more hydralazine to get the same blood pressure drop.

Clinical data bear this out. In one study, 81 percent of rapid acetylators needed 200 mg per day, compared with only 38 percent of slow acetylators. Even with those higher doses, blood pressure was controlled in just 27 percent of rapid acetylators versus 65 percent of slow acetylators.⁵ The relationship between acetylator status and hydralazine blood levels has been confirmed across a large body of work: a review found that fourteen out of fifteen studies showed a significant link, always in the same direction.⁶

Clinical pharmacogenetics guidelines now formally recognize this. A guideline from the Clinical Pharmacogenetics Implementation Consortium notes that slow acetylators (termed “NAT2 poor metabolizers”) are predicted to have higher plasma hydralazine levels, which can lead to both stronger blood pressure lowering and a greater chance of adverse effects, including drug-induced lupus.⁷ In practice, most patients do not get genotyped before starting hydralazine. But if you are a slow acetylator and you are taking a high dose, you may be getting far more active drug in your bloodstream than your prescriber expects.

How Food Changes Absorption

Whether you take hydralazine with food or on an empty stomach can meaningfully shift how much drug reaches your bloodstream, though the research findings are not entirely consistent. An early study found that food enhanced hydralazine’s bioavailability two- to threefold, regardless of whether coated or uncoated tablets were used.⁸ A later study confirmed that food intake does enhance both the bioavailability and the blood-pressure-lowering effect.⁹ A broader pharmacokinetic review also noted that food may enhance bioavailability.⁴

However, one study found the opposite: peak blood hydralazine levels dropped by about 46 percent after food, and the blood-pressure-lowering effect fell by roughly 42 percent. The authors suggested that food might speed the breakdown of hydralazine in the bloodstream and recommended patients take their doses at a consistent time relative to meals.¹⁰ The discrepancy likely reflects differences in assay methods and study design, but the practical takeaway is consistent: pick a pattern and stick with it. If you sometimes take hydralazine with a meal and sometimes on an empty stomach, you are essentially giving yourself a different dose each time.

Kidney Disease and Drug Accumulation

Your kidneys play a larger role in hydralazine’s behavior than many people realize. In patients with impaired kidney function, the drug’s half-life in the body increases dramatically. A study of patients with varying degrees of kidney impairment found that as kidney filtration rate dropped, the drug stuck around longer. In one patient whose kidneys were filtering at only about a sixth of the normal rate, hydralazine’s half-life reached nearly 16 hours, compared with roughly 1.7 to 3 hours in healthy volunteers. Among patients on long-term hydralazine, those with severely reduced kidney function showed clear drug accumulation at the same daily doses.¹¹

This accumulation is clinically relevant. If the drug is hanging around five to ten times longer than expected, a “normal” daily dose can produce blood levels that look more like a higher dose. People with significant kidney disease may need less hydralazine overall, and their prescribers usually adjust accordingly. The risk is highest in patients with a filtration rate below about 30 mL per minute, where the buildup becomes most pronounced.

The Lupus Risk and Why 200 mg Is a Practical Ceiling

The most feared long-term side effect of hydralazine is drug-induced lupus, an autoimmune condition where the body’s immune system begins attacking its own tissues. It is distinct from naturally occurring lupus but can produce real symptoms, including joint pain, skin rashes, fever, and, in some cases, fluid buildup around the heart. A case report documented a patient who developed recurring pericardial effusion after taking hydralazine for roughly one and a half to two years.¹² That case was unusual because the standard blood test used to screen for lupus came back negative, illustrating that the diagnosis is not always straightforward.

The risk of drug-induced lupus increases with both dose and duration. This is the main reason many prescribers treat 200 mg per day as the functional maximum, even though the label permits 300 mg. Slow acetylators face higher risk because more active drug reaches their bloodstream at any given dose, as described above. There is also a related but more serious concern: hydralazine-associated vasculitis, an inflammation of blood vessels. A large study found that higher daily doses of hydralazine (above 40 mg per day) were associated with about a 28 percent increase in the risk of vasculitis compared with lower doses.¹³ In a separate analysis, the median daily dose among patients who developed hydralazine-associated vasculitis was 150 mg, and the median time to onset was about 34 months.¹⁴

Drug-induced lupus and vasculitis generally improve after stopping hydralazine, though recovery can take weeks to months. The key point for dosing is that pushing above 200 mg per day adds only modest additional blood pressure benefit in most people while meaningfully increasing the chance of triggering an immune-mediated reaction, especially over months or years of use.

Why Hydralazine Is Almost Always Paired with Other Medications

You will rarely see hydralazine prescribed alone. When it lowers blood pressure by relaxing blood vessels, the body’s nervous system responds by speeding up the heart and retaining fluid, a compensation that can blunt the drug’s effect over time. This phenomenon, sometimes called pseudotolerance, is managed by adding a beta-blocker (to counteract the heart rate increase) and a diuretic (to prevent fluid retention). A clinical trial found that blood pressure was controlled in 31 of 37 patients using this triple combination, and a subsequent crossover comparing hydralazine to placebo within that regimen confirmed its contribution.¹⁵ The same study noted that starting the beta-blocker first was advisable, given the frequency of hydralazine-related side effects.

This means the total daily dose you need of hydralazine is shaped partly by which companion drugs you are taking. A well-chosen beta-blocker and diuretic can make a moderate dose of hydralazine much more effective than a high dose of hydralazine alone.

Different Dosing for Heart Failure

Hydralazine is also used in heart failure, but the context and dosing logic are different from its use in straightforward high blood pressure. The landmark application is the combination of hydralazine with isosorbide dinitrate, sold as the fixed-dose product BiDil. In a major trial of Black patients with advanced heart failure, the combination of hydralazine and isosorbide dinitrate added to standard therapy reduced the death rate by 43 percent compared with placebo, and the trial was stopped early because the benefit was so clear.¹⁶ Earlier work had shown that the two drugs together produced greater improvements in cardiac output and exercise capacity than either drug alone.¹⁷

In the heart failure setting, the target dose of hydralazine within the fixed-dose combination is typically 225 mg per day (75 mg three times daily), paired with isosorbide dinitrate. The goal is not just blood pressure lowering but reducing the workload on the heart by opening both arteries and veins. If you are taking hydralazine for heart failure, your prescriber is following a different dosing framework than someone using it purely for hypertension.

Intravenous Hydralazine in Emergencies

When blood pressure needs to come down urgently, such as during severe preeclampsia in pregnancy or a hypertensive emergency in a hospital setting, hydralazine can be given intravenously or by intramuscular injection. A typical IV dose is 5 to 10 mg, administered slowly over 10 to 15 minutes, and repeated every 20 to 30 minutes if needed.¹⁸ In a randomized trial comparing emergency antihypertensive drugs for severe preeclampsia, each dose of IV hydralazine was 10 mg diluted in saline, given up to three times within an hour.¹⁹

Intravenous hydralazine bypasses the gut and the first-pass metabolism that makes oral dosing so dependent on acetylator status. After IV administration, the acetylator phenotype is not a major factor in how the drug is cleared.⁴ This makes IV dosing somewhat more predictable than oral dosing, though the response can still be erratic. One of hydralazine’s known drawbacks in emergency settings is unpredictable hypotension, where blood pressure drops further or faster than expected.²⁰

Hydralazine in Pregnancy

Hydralazine has been one of the most widely used blood pressure drugs in pregnancy, particularly for preeclampsia and eclampsia. It has a long safety track record in terms of not being directly toxic to the fetus, which is why it remains in use even as alternatives have gained ground. However, a meta-analysis of trials comparing hydralazine to other antihypertensives in severe pregnancy hypertension found that hydralazine was associated with more maternal hypotension, more cesarean sections, more placental abruption, and more adverse effects on fetal heart rate. The authors concluded that the evidence does not support using hydralazine as a first-line choice for severe hypertension in pregnancy.²¹ Labetalol and nifedipine have increasingly taken that role. Still, hydralazine remains an option, particularly when other drugs are unavailable or contraindicated.

Pediatric Use

In children and adolescents, hydralazine is sometimes given intravenously in hospital settings for acute hypertension. Dosing is weight-based rather than fixed. A study of 141 IV hydralazine doses in hospitalized children found a median dose of 0.10 mg per kilogram of body weight. The drug reduced blood pressure by an average of about 19 percent. Nearly a third of children had what the researchers classified as an excessive response, where blood pressure dropped more than intended, and higher doses were linked to greater odds of that happening.²² This underscores a theme across all ages: hydralazine’s response is hard to predict, and starting low is prudent.

Older Adults and Fall Risk

In older patients, any blood-pressure-lowering medication carries the risk of making someone dizzy when they stand up, and hydralazine is no exception. A review of antihypertensive safety in older adults noted that all classes of blood pressure drugs, including direct vasodilators like hydralazine, can predispose older patients to symptomatic drops in blood pressure when standing or after eating, potentially leading to fainting or falls.²³ Because hydralazine’s effect can be unpredictable, and because older adults are more likely to have reduced kidney function that slows drug clearance, the practical maximum dose in this group is often lower than the textbook ceiling.

What Happens in an Overdose

Hydralazine overdose essentially amplifies the drug’s normal pharmacological action to a dangerous degree, producing severe low blood pressure, rapid heart rate, fainting, and nausea.²⁴ In at least one documented case of acute overdose in a young adult, the patient developed alarming electrocardiogram changes that looked like a heart attack, along with mild low blood pressure and acidic blood chemistry. The patient was managed conservatively in an intensive care unit and recovered fully as the drug cleared the system.²⁵ There is no specific antidote for hydralazine overdose; treatment focuses on IV fluids, vasopressors if blood pressure is dangerously low, and monitoring until the drug is metabolized. The relatively short half-life of hydralazine in people with normal kidney function works in the patient’s favor during an acute overdose.